Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of "Buy" from Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have been assigned an average rating of "Buy" from the eight analysts that are covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $71.40.

ARCT has been the topic of several recent research reports. HC Wainwright reissued a "buy" rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research report on Friday, November 8th. Leerink Partners started coverage on Arcturus Therapeutics in a research report on Monday, August 12th. They issued an "outperform" rating and a $70.00 target price on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. Finally, Leerink Partnrs raised Arcturus Therapeutics to a "strong-buy" rating in a research report on Monday, August 12th.

Insider Activity

In other news, COO Pad Chivukula sold 12,000 shares of the business's stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the sale, the chief operating officer now directly owns 435,334 shares in the company, valued at approximately $9,037,533.84. The trade was a 2.68 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 15.30% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. grew its stake in Arcturus Therapeutics by 54.6% during the 3rd quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company's stock worth $2,412,000 after buying an additional 36,714 shares during the last quarter. Geode Capital Management LLC grew its stake in Arcturus Therapeutics by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 551,798 shares of the biotechnology company's stock worth $12,810,000 after buying an additional 5,789 shares during the last quarter. XTX Topco Ltd grew its stake in Arcturus Therapeutics by 51.1% during the 3rd quarter. XTX Topco Ltd now owns 36,990 shares of the biotechnology company's stock worth $859,000 after buying an additional 12,509 shares during the last quarter. PDT Partners LLC bought a new position in Arcturus Therapeutics during the 3rd quarter worth $1,744,000. Finally, Verition Fund Management LLC bought a new position in Arcturus Therapeutics during the 3rd quarter worth $420,000. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Price Performance

NASDAQ ARCT traded up $0.83 on Friday, hitting $18.34. The company had a trading volume of 201,909 shares, compared to its average volume of 470,646. Arcturus Therapeutics has a 12-month low of $14.93 and a 12-month high of $45.00. The company has a market capitalization of $496.78 million, a PE ratio of -8.26 and a beta of 2.64. The company's fifty day moving average price is $19.91 and its 200-day moving average price is $23.28.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.44. The firm had revenue of $41.67 million for the quarter, compared to analyst estimates of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same period in the previous year, the company posted ($0.61) EPS. On average, sell-side analysts anticipate that Arcturus Therapeutics will post -2.31 EPS for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.